Opinion|Videos|February 27, 2025
Initial Treatment Options for Liver-Confined Unresectable HCC
Author(s)Amit Singal, MD
The panelist discusses first-line options including atezolizumab plus bevacizumab, lenvatinib, and sorafenib. Second-line treatments include regorafenib, cabozantinib, and ramucirumab. Clinical trials should be prioritized when available.
Advertisement
Video content above is prompted by the following:
- Please briefly review the treatment options for patients with hepatocellular carcinoma (HCC) confined to the liver but unresectable according to NCCN guidelines.
- Please discuss standard treatment modalities and share your impressions on the initial treatment approach in this case.
Advertisement
Related to this article
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
5